Anti-Therapeutic Action: Dissociation

Comparative Efficacy and Functional Outcomes of Psychedelic-Assisted Therapies in Treatment-Resistant Depression: A Systematic Review of Recent Clinical Trials

mycolabadmin

This systematic review examines how psychedelic-assisted therapies like ketamine and psilocybin help people with severe, treatment-resistant depression that doesn’t respond to standard antidepressants. The analysis of 10 recent clinical trials shows these therapies work quickly, often providing symptom relief within days rather than weeks, and importantly, they also help people return to work and daily functioning. These treatments are generally well-tolerated with minimal cognitive side effects, suggesting they could become important new options for patients who haven’t benefited from conventional depression treatments.

Read More »

Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome

mycolabadmin

This study examined whether the psychological experiences people have while taking ketamine or psilocybin—such as feeling disconnected or having spiritual insights—are actually responsible for their mental health improvements. Researchers analyzed 23 studies and found that these subjective experiences explain about 10% of ketamine’s benefits and 24% of psilocybin’s benefits. Psilocybin’s effects appear more connected to therapeutic outcomes than ketamine’s, and both drugs showed stronger connections between subjective effects and treatment success in substance use disorder compared to depression.

Read More »

Development of the Japanese version of the Challenging Experience Questionnaire

mycolabadmin

Researchers have translated an important measurement tool called the Challenging Experience Questionnaire into Japanese. This tool helps doctors and researchers measure difficult feelings like fear and anxiety that people sometimes experience when taking psilocybin mushrooms as part of therapy. Having this questionnaire available in Japanese is important because it allows Japanese patients and researchers to participate in psychedelic research and understand these experiences better.

Read More »

The central role of the Thalamus in psychosis, lessons from neurodegenerative diseases and psychedelics

mycolabadmin

This paper explores how the thalamus, a key brain structure controlling attention and perception, malfunctions in Parkinson’s disease and similar neurological conditions, causing hallucinations and delusions. Interestingly, these symptoms resemble the altered mental states produced by psychedelic drugs like LSD and psilocybin. By studying both conditions together, researchers found that a common mechanism called thalamocortical dysrhythmia disrupts how the brain filters information and processes reality, offering new insights for treating psychotic symptoms.

Read More »

New and emerging pharmacologic treatments for MDD

mycolabadmin

Major depressive disorder affects millions worldwide and current antidepressants often don’t work well or take weeks to be effective. Researchers have developed exciting new treatments that work through different brain mechanisms and show promise for rapid symptom relief. These include nasal spray ketamine (approved 2019), oral medications like zuranolone (approved 2023), and investigational treatments including psilocybin, which show benefits especially for treatment-resistant cases. While many show great promise, more research is needed on long-term safety and how to make them widely available.

Read More »

A Review of the Food and Drug Administration Pipeline and Proposed California Legislation on Medicinal Psychedelics

mycolabadmin

Psychedelic compounds like psilocybin and ketamine show promise in treating serious mental health conditions including PTSD and depression. The FDA carefully evaluates these drugs through multi-phase clinical trials to ensure they are safe and effective. While California has proposed making psychedelics more widely available through legislation, the FDA’s thorough approval process provides important protections by identifying potential risks and ensuring proper medical oversight.

Read More »

Recalled childhood trauma and post-psychedelic trajectories of change in a mixed-methods study

mycolabadmin

This study examined how childhood trauma can resurface during psychedelic experiences and what happens afterward. Researchers surveyed over 600 people who had difficult experiences after using psychedelics, and interviewed 18 of them in detail. They found that trauma surfaced in different ways—some people vividly relived events, others felt intense bodily sensations, and some experienced confusion. About half of participants found healing from the experience, while others struggled with ongoing trauma symptoms or mixed outcomes. The research emphasizes the importance of proper preparation, supportive settings, and follow-up integration work to help people process these experiences safely.

Read More »
Scroll to Top